Brain

Coave Therapeutics Launches coAAV-CSF-01, a Novel CNS-Targeted Gene Therapy Vector for Neurodegenerative and other CNS DiseasesCoave Therapeutics Launches coAAV-CSF-01, a Novel CNS-Targeted Gene Therapy Vector for Neurodegenerative and other CNS Diseases

Coave Therapeutics Launches coAAV-CSF-01, a Novel CNS-Targeted Gene Therapy Vector for Neurodegenerative and other CNS Diseases

New breakthrough data from studies with Coave’s ALIGATER™-engineered AAV2-based capsid coAAV-CSF-01 (S01coAAV2) demonstrates improved brain tissue transduction and safety following…

1 month ago
Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell HealthCognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health

Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health

PURCHASE, N.Y., May 09, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc.  (NASDAQ: CGTX), a clinical-stage company developing drugs that treat…

1 month ago
Zilia Closes Bridge Round with Participation from Existing and New Investors Including Linearis VenturesZilia Closes Bridge Round with Participation from Existing and New Investors Including Linearis Ventures

Zilia Closes Bridge Round with Participation from Existing and New Investors Including Linearis Ventures

QUEBEC CITY, May 7, 2025 /PRNewswire/ - Zilia Inc. (''Zilia''), a medical technology company pioneering the use of the eye…

1 month ago
Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and WebcastMoleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast

Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast

HOUSTON, May 07, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company…

1 month ago
Pramana Strengthens Scientific Leadership with Addition of Dr. Adrian Noriega to Advance Neurodegenerative PipelinePramana Strengthens Scientific Leadership with Addition of Dr. Adrian Noriega to Advance Neurodegenerative Pipeline

Pramana Strengthens Scientific Leadership with Addition of Dr. Adrian Noriega to Advance Neurodegenerative Pipeline

VANCOUVER, British Columbia, May 07, 2025 (GLOBE NEWSWIRE) -- Pramana Pharmaceuticals, a late-stage preclinical biopharmaceutical company developing a transformative small…

1 month ago
Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA CongressAlterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress

Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress

ATH434 Phase 2 Data to be Presented at Opening Plenary SessionMELBOURNE, Australia and SAN FRANCISCO, May 07, 2025 (GLOBE NEWSWIRE)…

1 month ago
Radiopharm Theranostics to Participate in the D. Boral Capital Inaugural Global ConferenceRadiopharm Theranostics to Participate in the D. Boral Capital Inaugural Global Conference

Radiopharm Theranostics to Participate in the D. Boral Capital Inaugural Global Conference

SYDNEY, May 07, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company…

1 month ago
Trogenix Further Strengthens its Scientific Advisory Board with the Appointment of World-Leading Experts, Prof Nada Jabado and Prof Burkhard BecherTrogenix Further Strengthens its Scientific Advisory Board with the Appointment of World-Leading Experts, Prof Nada Jabado and Prof Burkhard Becher

Trogenix Further Strengthens its Scientific Advisory Board with the Appointment of World-Leading Experts, Prof Nada Jabado and Prof Burkhard Becher

Trogenix Further Strengthens its Scientific Advisory Board with the Appointment of World-Leading Experts, Prof Nada Jabado and Prof Burkhard Becher…

1 month ago
CervoMed to Participate in H.C. Wainwright 3rd Annual BioConnect Investor ConferenceCervoMed to Participate in H.C. Wainwright 3rd Annual BioConnect Investor Conference

CervoMed to Participate in H.C. Wainwright 3rd Annual BioConnect Investor Conference

BOSTON, May 07, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for…

1 month ago
BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson’s Disease and Related Disorders (IAPRD 2025)BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson’s Disease and Related Disorders (IAPRD 2025)

BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson’s Disease and Related Disorders (IAPRD 2025)

CARSON CITY, Nev., May 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company…

1 month ago